To ATCC Valued Customers,

ATCC stands ready to support our customers’ needs during the coronavirus pandemic. Our first job is to listen to and observe what our customers need, and meet those needs with quality products and services. While we are not currently experiencing delays due to this pandemic, we expect that we could see them as the situation evolves. If you experience any issues, please contact ATCC Customer Service at For Technical questions please contact Thank you for your understanding, patience and flexibility as ATCC does everything it can to help reduce the impact of the coronavirus pandemic to our valued customers.

UACC-812 (ATCC® CRL-1897)

Organism: Homo sapiens, human  /  Tissue: mammary gland; breast  /  Disease: ductal carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
mammary gland; breast
Product Format frozen
Morphology epithelial
Culture Properties adherent
Biosafety Level 1

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

Disease ductal carcinoma
Age 43 years
Gender female
Storage Conditions liquid nitrogen vapor phase
Karyotype range = 58 to 64; abnormal banding region in 3p
This cell line was established by A. Liebovitz and associates in 1986 from breast tissue removed at mastectomy to remove a ductal carcinoma (stage II, grade IV).
Clinical Data
Prior to surgery, the patient had received extensive chemotherapy.
Receptor Expression
estrogen receptor (negative), progesterone receptor (negative)
Prior to surgery, the patient had received extensive chemotherapy.
The cells exhibit a 15 fold amplification of the HER-2/neu oncogene sequence.
They are negative for estrogen receptors, progesterone receptors and P glycoprotein.
Complete Growth Medium Leibovitz's L-15 medium with 2 mM L-glutamine supplemented with 20 ng/ml human EGF and 20% fetal bovine serum.

(Note: The L-15 medium formulation was devised for use in a free gas exchange with atmospheric air. A CO2 and air mixture is detrimental to cells when using this medium for cultivation)

Subculturing Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
  1. Remove and discard culture medium.
  2. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor.
  3. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
    Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.
  4. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting.
  5. Add appropriate aliquots of the cell suspension to new culture vessels.
  6. Incubate cultures at 37°C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:3 is recommended
Medium Renewal: Every 2 to 3 days

Note: The cells grow very slowly, and growth is enhanced by using 20% fetal bovine serum and adding epidermal growth factor (20 ng/mL) to the medium.

Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 100%
Temperature: 37°C
STR Profile Amelogenin: X
CSF1PO: 11
D13S317: 12
D16S539: 8, 11
D5S818: 11, 12
D7S820: 9
TH01: 9
TPOX: 8, 11
vWA: 16
Population Doubling Time 100 hrs
Name of Depositor A Liebovitz, J Trent
Deposited As Homo sapiens
Year of Origin 1986

Proc. Am. Assoc. Cancer Res. 29: 24, 1988.

Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation

The breast carcinoma UACC-812 was deposited in the ATCC by Albert Leibovitz and Jeffrey M. Trent, Arizona Cancer Center, University of Arizona, Tucson, Arizona. The cells are distributed for research purposes only. The University of Arizona has released the line subject to the following: 1. UACC-812 or their products MUST NOT BE DISTRIBUTED to third parties. Commercial interests are the exclusive property of the University of Arizona. 2. Any proposed commercial use of these cells must first be negotiated with the Director of the Arizona Cancer Center, University of Arizona, 1501 N. Campbell Avenue, Tucson, Arizona 85724. Telephone (602) 626-7925, FAX (602) 626-2284. 3. In all papers reporting any use of these of these cells or derived products, a direct reference will be made to the original publication given above.


Proc. Am. Assoc. Cancer Res. 29: 24, 1988.

Meltzer P, et al. Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. Br. J. Cancer 63: 727-735, 1991. PubMed: 1674877